Smoking May Thin the Brain
Philadelphia, PA, 2 December 2010 - Many brain imaging studies have reported that tobacco smoking is associated with large-scale and wide-spread structural brain abnormalities.
The cerebral cortex is a specific area of the brain responsible for many important higher-order functions, including language, information processing, and memory. Reduced cortical thickness has been associated with normal aging, reduced intelligence, and impaired cognition. However, prior research had not described the impact of smoking upon cortical thickness.
A new study, published in the current issue of Biological Psychiatry, now reports concerning findings about the impact of smoking.
Researchers compared cortical thickness in volunteers, both smokers and never-smokers, who were without medical or psychiatric illnesses.
Smokers exhibited cortical thinning in the left medial orbitofrontal cortex. In addition, their cortical thickness measures negatively correlated with the amount of cigarettes smoked per day and the magnitude of lifetime exposure to tobacco smoke. In other words, heavier smoking was associated with more pronounced thinning of cortical tissue.
The orbitofrontal cortex has frequently been implicated in drug addiction. The current findings suggest that smoking-related cortical thinning may increase the risk for addictions, including smoking.
“Since the brain region in which we found the smoking-associated thinning has been related to impulse control, reward processing and decision making, this might explain how nicotine addiction comes about,” explained Dr. Simone Kühn. “In a follow-up study, we plan to explore the rehabilitative effects of quitting smoking on the brain.”
“The current findings suggest that smoking may have a cumulative effect on the brain,” noted John Krystal, M.D., Editor of Biological Psychiatry and Professor and Chair of Psychiatry at Yale University. “This concerning finding highlights the importance of targeting young smokers for antismoking interventions.” For now, this study adds to a long and ever-growing list of reasons that smokers should consider quitting.
# # #
Notes to Editors:
The article is “Reduced Thickness of Medial Orbitofrontal Cortex in Smokers” by Simone Kühn, Florian Schubert, and Jürgen Gallinat. Kühn and Gallinat are affiliated with St. Hedwig Krankenhaus, Clinic for Psychiatry and Psychotherapy, Charité University Medicine, Berlin, Germany. Kühn is also affiliated with the Faculty of Psychology and Educational Sciences, Department of Experimental Psychology and Ghent Institute for Functional and Metabolic Imaging, Ghent University, Ghent, Belgium, and also the Institute of Cognitive Neuroscience, Department of Psychology, University College London, London, United Kingdom. Schubert is with Physikalisch-Technische Bundesanstalt, Department of Medical Metrology, Berlin, Germany.
The article appears in Biological Psychiatry, Volume 68, Number 11 (December 1, 2010), published by Elsevier.
The authors’ disclosures of financial and conflicts of interests are available in the article.
John H. Krystal, M.D. is Chairman of the Department of Psychiatry at the Yale University School of Medicine and a research psychiatrist at the VA Connecticut Healthcare System. His disclosures of financial and conflicts of interests are available at http://journals.elsevierhealth.com/webfiles/images/journals/bps/Biological-Psychiatry-Editorial-Disclosures-7-22-10.pdf.
Full text of the article mentioned above is available upon request. Contact Chris J. Pfister at firstname.lastname@example.org to obtain a copy or to schedule an interview
About Biological Psychiatry
This international rapid-publication journal is the official journal of the Society of Biological Psychiatry. It covers a broad range of topics in psychiatric neuroscience and therapeutics. Both basic and clinical contributions are encouraged from all disciplines and research areas relevant to the pathophysiology and treatment of major neuropsychiatric disorders. Full-length reports of novel results, commentaries, case studies of unusual significance, and correspondence judged to be of high impact to the field are published, particularly those addressing genetic and environmental risk factors, neural circuitry and neurochemistry, and important new therapeutic approaches. Concise reviews and editorials that focus on topics of current research and interest are also published rapidly.
Biological Psychiatry (www.sobp.org/journal) is ranked 4th out of 117 Psychiatry titles and 13th out of 230 Neurosciences titles in the 2009 ISI Journal Citations Reports® published by Thomson Reuters. The 2009 Impact Factor score for Biological Psychiatry has increased to 8.926.
Elsevier is a world-leading provider of information solutions that enhance the performance of science, health, and technology professionals, empowering them to make better decisions, deliver better care, and sometimes make groundbreaking discoveries that advance the boundaries of knowledge and human progress. Elsevier provides web-based, digital solutions — among them ScienceDirect, Scopus, Elsevier Research Intelligence and ClinicalKey— and publishes over 2,500 journals, including The Lancet and Cell, and more than 33,000 book titles, including a number of iconic reference works. Elsevier is part of RELX Group plc, a world-leading provider of information solutions for professional customers across industries. www.elsevier.com
Chris J. Pfister
Strategic Marketing Manager - Elsevier